Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2017 16:01 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Proposed Public Offering

TORONTO, ONTARIO--(Marketwired - May 25, 2017) - Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
May 12, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Reports First Quarter 2017 Financial and Operating Results

TORONTO, ONTARIO--(Marketwired - May 12, 2017) - Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
April 03, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update

TORONTO, ONTARIO--(Marketwired - April 3, 2017) - Trillium Therapeutics Inc. (TSX:TRIL) (NASDAQ:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the...
March 29, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Present at Investor and Scientific Conferences in April

TORONTO, ONTARIO--(Marketwired - March 29, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the...
March 10, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Reports Annual 2016 Financial and Operating Results

TORONTO, ONTARIO--(Marketwired - March 10, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
February 24, 2017 11:30 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621

TORONTO, ONTARIO--(Marketwired - Feb. 24, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the...
February 15, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial

TORONTO, ONTARIO--(Marketwired - Feb. 15, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the...
February 07, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Present at Investor and Scientific Conferences in February

TORONTO, ONTARIO--(Marketwired - Feb. 7, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the...
February 02, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Outlines Anticipated Activities and Milestones for 2017

TORONTO, ONTARIO--(Marketwired - Feb. 2, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the...
January 31, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial

TORONTO, ONTARIO--(Marketwired - Jan. 31, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for the...